• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cell biology international. >Apoptosis in raloxifene-treated postmenopausal women.
【24h】

Apoptosis in raloxifene-treated postmenopausal women.

机译：雷洛昔芬治疗的绝经后妇女的细胞凋亡。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

As raloxifene is a mixed estrogen receptor agonist and antagonist, it exerts different effects on apoptosis in different tissues. In this study, we aimed to evaluate apoptosis in the peripheral lymphocytes of postmenopausal women treated with raloxifene and compare it with untreated control subjects. In this way, we expected to deduce some results about the effect of raloxifene on the immune system and to serve as a guide for future studies on this newly proposed effect of a well-known agent. Twenty osteoporotic postmenopausal women treated with raloxifene for 12 months were included in this study. Another 20 osteoporotic postmenopausal women matched for age and postmenopausal years, but without any medication, were chosen as the control group. Apoptosis was evaluated using a morphological and DNA fragmentation assay, in the peripheral lymphocytes of these women. Our results revealed a decrease in the apoptosis percentages of the patients treated with raloxifene (14.6%) with respect to the control subjects (15.8%), but the difference was not statistically significant (p=0.467). This study indicated that raloxifene treatment had no apoptotic effect on peripheral human lymphocytes compared to controls.
机译：由于雷洛昔芬是雌激素受体激动剂和拮抗剂的混合体，因此对不同组织的细胞凋亡具有不同的作用。在这项研究中，我们旨在评估接受雷洛昔芬治疗的绝经后妇女外周淋巴细胞的凋亡，并将其与未经治疗的对照组进行比较。通过这种方式，我们期望得出有关雷洛昔芬对免疫系统影响的一些结果，并为将来对这种新近提出的已知作用的研究提供指导。这项研究包括了接受雷洛昔芬治疗12个月的20名绝经后骨质疏松妇女。选择年龄和绝经后年龄相匹配但没有任何药物治疗的另外20名骨质疏松绝经后妇女作为对照组。使用形态学和DNA片段化分析评估了这些女性外周血淋巴细胞的凋亡。我们的结果表明，相对于对照组（15.8％），雷洛昔芬治疗的患者的细胞凋亡百分比降低了（14.6％），但差异无统计学意义（p = 0.467）。这项研究表明，与对照组相比，雷洛昔芬治疗对周围人淋巴细胞没有凋亡作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号